Dr. Lilangi Ediriwickrema, MD

Dr. Ediriwickrema practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Ediriwickrema's NPI, 1588922801, was assigned on April 24, 2012. Dr. Ediriwickrema graduated from Yale School of Medicine in 2012. Dr. Ediriwickrema holds California license A131244.

Dr. Ediriwickrema's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Ediriwickrema's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Ediriwickrema to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ediriwickrema practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Ediriwickrema's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Ediriwickrema is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Ediriwickrema is licensed in California.

Dmand AI lists age-related macular degeneration, cataract, cold sores or genital herpes, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and shingles among the conditions Dr. Ediriwickrema treats.

CMS data shows 1,243 Medicare services from Dr. Ediriwickrema across 14 procedure codes in 2024, for 374 Medicare patients. Medicare paid $107,808 for them.

CMS counts 374 Medicare patients who saw Dr. Ediriwickrema in 2024. The largest group is 75 to 84, with 159 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ediriwickrema's median patient age at 70, with 65% women.

In 2024, Dr. Ediriwickrema wrote 494 Medicare Part D claims for 197 patients. 74% of them were for generic drugs. CMS names the drug for 383 of them, across 8 drugs with 11 or more claims each, at $5,211 in total drug cost. In 2023, CMS named 175 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Ediriwickrema for performance year 2024, reported through an alternative payment model (APM). Dr. Ediriwickrema accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ediriwickrema as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 32 papers to Dr. Ediriwickrema, published from 2015 to 2024. 2018 was the busiest year, with 5. The most frequent topics are Orbit, Decompression, Surgical and Graves Ophthalmopathy. Dr. Ediriwickrema has published most often in Ophthalmic Plast Reconstr Surg. Dr. Ediriwickrema's most frequent co-authors are Don O. Kikkawa, MD, Bobby S. Korn, MD and Archana Appukuttan Nair, MD.

CMS Open Payments shows 5 general payments to Dr. Ediriwickrema from 4 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 64% of the total. Stryker Corporation paid the most, $237.

Dr. Ediriwickrema graduated from Yale School of Medicine in 2012.

Dr. Ediriwickrema is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.